RA0150

antibody from Oursmab

Targeting: CSF1 M-CSF, MCSF, MGC31930

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0150

Provider

Oursmab

Product name

Lacnotuzumab (Biosimilar Reference Antibody) (CSF1)

Antibody type

Monoclonal

Description

Lacnotuzumab (also known as MCS110) is a human monoclonal antibody that targets colony-stimulating factor 1 (CSF-1 or M-CSF). It functions by binding to and neutralizing circulating CSF-1, thereby inhibiting its interaction with the CSF-1 receptor (CSF-1R) on target cells. This blockade aims to deplete tumor-associated macrophages (TAMs), particularly the pro-tumorigenic M2 phenotype, within the tumor microenvironment. By modulating the immune landscape, Lacnotuzumab seeks to enhance anti-tumor immunity and has been investigated in clinical trials for the treatment of various solid tumors, such as tenosynovial giant cell tumor (TGCT) and certain advanced cancers, often in combination with other therapies.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.